CITY-OF-ESPOO
31.5.2022 08:02:12 CEST | Business Wire | Press release
At the three-day conference that brings the management of European cities together, the topics discussed include the inclusion of young people, co-creation and cities’ leadership in the work against climate change. The theme of the annual conference, An Era of New Beginnings, consists of three parts, Dream, Act and Lead, through which these topics are studied. The conference attendees include city leadership from Oslo, Rotterdam, Helsinki, Brussels, Stockholm and Munich, among other cities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005019/en/
On Friday, one of the keynote speakers will be Executive Vice-President of the European Commission Frans Timmermans , who will introduce the discussion on climate-neutral cities.
“Cities play a key role in the progress towards the EU’s climate goals and building a sustainable future. The annual conference also strengthens the dialogue between cities and the European Commission. However, achieving the goals will be impossible if cities cannot extensively involve operators from all sectors of society. Co-creation and cooperation between the public and private sector are some of the overarching themes of the conference, in addition to climate leadership and young people’s inclusion,” says Milla Ovaska , Head of International Affairs at the City of Espoo.
As a part of the conference and the European Year of Youth, Espoo is organising the Future Mentors programme in which young people living in European cities engage in dialogue with the policymakers of their cities. This is called reverse mentoring.
“We wanted to provide young people with an opportunity to voice their dreams, wishes and concerns about the future of their home city. The decisions that we are making now will have long-term influence, and young people will be the ones living in the future we create. We would like the programme to encourage policymakers to engage in dialogue and give space to new ways of thinking,” says Marianne Julkunen , Partnership Coordinator.
Eurocities Awards to best practices of resident inclusion
On the evening of Thursday 9 June, the conference programme includes the Eurocities Awards ceremony , which showcases the member cities’ projects that have succeeded best in involving their residents and influencing their quality of life. This year’s awards will be given in three categories: ‘Future generations transforming the cities,’ ‘Skills and competences for the future’ and ‘Scalable solutions for positive climate impact.’ The winners will be selected by a five-person jury.
Representatives of the media are cordially invited to attend the annual Eurocities conference on-site at Espoo, Finland. The conference is also available virtually on its website .
#Eurocities2022
#FutureMentors2022
The conference has been created in collaboration with various organisations, all relevant to building future-proof cities and societies. The main partners are Aalto University and VTT. You can find all partners at: eurocities2022.eu/partners .
Eurocities is the key network of European cities for Espoo. Eurocities supervises interests at the level of the EU, generates information about the EU’s funding application rounds and EU legislation, and functions as a peer learning platform for its member cities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
